Skip to main content
Premium Trial:

Request an Annual Quote

Takara Bio USA to Acquire Rubicon Genomics

NEW YORK (GenomeWeb) – Takara Bio USA Holdings announced today that it has signed an agreement to acquire all outstanding capital stock of privately held Rubicon Genomics for $75 million.

Further terms were not disclosed.

Takara Bio USA Holdings said the deal will help its parent company — Shiga, Japan-based Takara Bio Group — to expand its portfolio of products for next-generation sequencing library preparation and genetic analysis, strengthen its position in low-input and single-cell pre-analytical sample preparation, and expand into new clinical markets such as in vitro fertilization.

Rubicon sells a number of DNA library preparation products for arrays and Illumina NGS platforms under the ThruPlex, PicoPlex, and TransPlex brand names.

"This acquisition builds on Takara Bio Group's commitment to develop a differentiated NGS portfolio and provide our customers with a broader offering of genetic analysis solutions, particularly in the area of library preparation," Takara Bio USA Holdings President Carol Lou said in a statement. "Rubicon's technologies and products complement our current expertise and offerings such as our portfolio of cDNA synthesis, low-input, and single-cell RNA-seq products. … [We] are looking forward to strengthening and expanding our product offerings in the fields of genomics, sequencing, single-cell, and clinical applications with their unique technologies."

Takara Bio USA Holdings also said that Rubicon's technologies complement those of WaferGen Bio-systems, which it agreed to acquire earlier this year. That deal is expected to close in March.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.